Watch More Highlights

Sheeba Cantanelli, MPAS, PA-C, of UT Southwestern Simmons Cancer Center, discusses phase III results of a study which showed that when entinostat, an orally bioavailable HDAC inhibitor, is combined with exemestane, it can improve progression-free survival compared with exemestane alone in patients with advanced hormone receptor–positive, HER2- negative breast cancer that progressed after previous endocrine therapy. This regimen may benefit these patients with an unmet medical need (Abstract GS1-06).

Copyright © 2010-2021 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.